Skip to main content
. 2020 Feb 5;12(2):132. doi: 10.3390/pharmaceutics12020132

Figure 4.

Figure 4

In vivo cellular degradation and distribution. (a) T-DM1, EGF, and cetuximab degradation in tumor cells. At 24 h EGF (a rapidly clearing protein), is mostly degraded in the tumor. However, the slowly clearing cetuximab and T-DM1 show mostly intact protein. Over 48–72 h, after maximum uptake is reached, T-DM1 is increasingly degraded. Data plotted as mean ± standard deviation. (b) Fluorescence biodistribution of EGF, cetuximab, and A33 at 24 h and T-DM1 at 24, 48, and 72 h.